Literature DB >> 35343368

CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.

Brandy Perkins1, Margaret Showel1, Laura Schoch1, Philip H Imus1, Theodoros Karantanos1, Raluca Yonescu1, Laura Morsberger1, Gabriel Ghiaur1, Douglas E Gladstone1, Richard J Jones1.   

Abstract

The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Immunoglobulin heavy chain variable region (IgHV) mutation status is among the most important prognostic factors, with unmutated IgHV associated with inferior outcomes. CLL presumably arises from mature B cells. However, we hypothesized that IgHV unmutated CLL could arise early in B cell differentiation. We prospectively studied 29 patients with mutated and 88 with unmutated IgHV CLL for the presence of CD34+CD19+ cells harboring CLL chromosomal abnormalities. CD34+CD19+ cells were never detected in mutated CLL. In contrast, a small but distinct population of CD34+CD19+ cells harboring the CLL chromosomal abnormality was present in 86/88 patients with unmutated IgHV across all cytogenetic subtypes. Moreover, the CD34+CD19+ cells generated a 3.8 ± 0.7 fold CLL cell expansion over 3-4 weeks in cultures containing IL-3 and IL-2. Unmutated IgHV CLL appears to arise in CD34+ B cells, which perhaps contributes to its poorer prognosis.

Entities:  

Keywords:  CD19; CD34; Chronic lymphocytic leukemia (CLL); stem cells

Mesh:

Substances:

Year:  2022        PMID: 35343368      PMCID: PMC9276631          DOI: 10.1080/10428194.2022.2038375

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  34 in total

Review 1.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 2.  Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.

Authors:  Sameer A Parikh; Paolo Strati; Mazie Tsang; Colin P West; Tait D Shanafelt
Journal:  Blood       Date:  2016-02-03       Impact factor: 22.113

Review 3.  Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy.

Authors:  Hans Erik Johnsen; Kim Steve Bergkvist; Alexander Schmitz; Malene Krag Kjeldsen; Steen Møller Hansen; Michael Gaihede; Martin Agge Nørgaard; John Bæch; Marie-Louise Grønholdt; Frank Svendsen Jensen; Preben Johansen; Julie Støve Bødker; Martin Bøgsted; Karen Dybkær
Journal:  Leuk Lymphoma       Date:  2013-11-01

Review 4.  Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.

Authors:  Theodoros Karantanos; Richard J Jones
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia.

Authors:  Seongseok Yun; Ling Zhang; Manish R Patel; Todd C Knepper; Julio C Chavez; Javier Pinilla-Ibarz
Journal:  Blood       Date:  2018-02-05       Impact factor: 22.113

6.  Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.

Authors:  P Panayiotidis; D Jones; K Ganeshaguru; L Foroni; A V Hoffbrand
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

7.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

8.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia.

Authors:  L Trentin; R Zambello; C Agostini; C Enthammer; A Cerutti; F Adami; S Zamboni; G Semenzato
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

10.  The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Authors:  Daniel L Van Dyke; Lillian Werner; Laura Z Rassenti; Donna Neuberg; Emanuella Ghia; Nyla A Heerema; Paola Dal Cin; Marie Dell Aquila; Chandrika Sreekantaiah; Andrew W Greaves; Thomas J Kipps; Neil E Kay
Journal:  Br J Haematol       Date:  2016-02-05       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.